STAT Plus: A biotech company misled investors about its dealings with FDA. It’s time for a reckoning
The FDA cannot talk publicly about the meetings it has with companies during the drug development process. And companies exploit that opportunity.
Suscribirse a:
Enviar comentarios (Atom)
.png)
No hay comentarios:
Publicar un comentario